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1. Introduction 
We are on the threshold of a paradigm shift for proteomics, moving from largely a 
qualitative discipline, to now being capable of quantification of a protein within a complex 
sample at great sensitivity. The potential application of such advanced proteomic 
technology is enormous as we will be able to detect and quantify low levels of expressed 
proteins in complex samples, and so move comparative proteomics to a new level.  
The evolving practice of personalized medicine will be dependent on devising new 
techniques and methodologies that will allow the detection and quantification of proteins 
that are implicated in contributing to the diseased state. There is perhaps somewhere over 
5000 genes that are linked to disease states and complex networks of interactions of these 
expressed genes ultimately lead to these disease states. The myriad of single nucleotide 
polymorphisms (SNPs) contribute to such phenomena, as an individual’s SNP profile play a 
major role in susceptibility to disease and in adverse reactions to drugs, for example. 
Coupled with mutations that occur throughout life, the complex “disease state” proteome 
will contain mutant proteins at low levels that need to be identified and quantified, so that 
therapeutic intervention based on rational scientific hypotheses can be investigated.  
Plasma and serum contain an unknown number of proteins with amounts ranging from pg-
g/L levels (i.e. very high dynamic range). As we know one of the major problems faced by 
proteomic studies of plasma or serum, or indeed any complex protein sample, is that a 
relatively small number of abundant proteins accounts for the great majority of protein 
content of the sample. The upshot is that the proteins of interest, which may have regulatory 
function, are masked by these abundant proteins, and non-targeted methods of proteomic 
analysis bias at the top end of the abundance scale. The development of new methods for 
quantifying low abundance proteins has evolved rapidly, concomitant with the evolution of 
powerful mass spectrometers of increasing sensitivity. The use of antibodies for targeting 
peptides prior to mass spectrometry analysis is becoming prominent, as a means of 
partitioning low abundance peptides away from peptides in the bulk sample. 
This review will provide a broad overview of the evolution of proteomic methods to analyse 
biological samples, including Differential In-Gel Electrophoresis (DIGE), Isotope-Coded 
Affinity Tag (ICAT), Isobaric tags for relative and absolute quantification (iTRAQ), Stable 
isotope labeling with amino acids in cell culture (SILAC), Unique ion signature Mass 
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Spectrometry, Selected reaction monitoring (SRM)- based targeted mass spectrometry and 
Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). Examples of 
the application of these methods to the identification of proteins involved in a variety of 
disease states and their implication for personalized medicine will be provided.  
2. Overview of personalized medicine 
Personalized medicine is designed medicine based on the genotype, or more specifically the 
SNP profile of individuals. Personalized medicine facilitates the selection of treatments best 
matched to the individual and disease phenotype (Marko-Varga et al., 2007). What are the 
main factors which contribute to genotype diversity? SNP is the overriding factor, reflecting 
past mutation, and occurs wherever there is more than one nucleotide when comparing two 
sequences. It is the spread of SNPs within genomes which contribute to our individuality, 
with an estimated 93% of genes containing an SNP (Chakravati, 2001). The individual 
“fingerprint” of SNPs reflects differences in susceptibility to disease and our varying 
response to drugs. Pharmacogenetics is the study of how these differences in genotype are 
manifested in inter-individual variation in response to drugs. The convergence of traditional 
pharmacogenetics with the relatively new discipline of human genomics has resulted in the 
evolution of pharmacogenomics (Weinshilbaum et al., 2004). The Pharmacogenetics and 
Pharmacogenomics Knowledge Base (PharmGKB) is an entity associated with the cataloging 
genes involved in modulating the response to drugs. The Pharmacogenomics Research 
Network (PGRN) is a collaboration of scientists studying the effect of genes on 
responsiveness to a wide variety of medicines (Altman, 2007). The PGRN is linked to the 
PharmGKB integrative database containing genetic and clinical information on participants 
in studies (http:www.pharmgkb.org). Thus the integration and availability of data 
associated with information at the genomic and transcriptomic levels are well developed 
and a valuable resource for researchers involved in the development of personalized 
medicine.  
The incorporation of proteomics in the further development of the concept of personalized 
medicine is a more recent phenomenon, and has given rise to the area of 
pharmacoproteomics, which in essence studies how the proteome changes in response to a 
drug, and is a logical extension of the pharmacogenetics and pharmacogenomics (Jain, 
2004). While pharmacogenetics and pharmacogenomics provide information at the level of 
the genome and transcriptome, pharmacoproteomics yields information on function (i.e. 
translational level), although it should be pointed out that small nuclear (sn) RNAs have 
relatively recently been shown to contribute to regulation of cellular processes and thus 
have a functional role (Mercer et al., 2009; Mattick, 2009). To this end proteomics and 
proteomic profiling of individuals’ serum and tissues are becoming increasingly important 
in patient diagnosis and assessment, and together with pharmacogenetics and 
pharmacogenomics, will provide a more complete picture of the status of an individual, 
particularly at the functional level.  
Identification of disease states can be based on genomic analyses. For example, 
identification of mutations in breast cancer genes BRAC1 and BRAC2 can be used in the 
diagnosis of breast cancer (Miki et al., 1994; Wooster et al., 1995). However, at present 
DNA alone does not necessarily reflect the physiological state of functioning cells and 
thus analysis of gene products, both RNA and protein are required. RNA expression in 
comparison to protein, is easier to perform, but transcript levels in the cell do not always 
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reflect protein levels, nor account for post-translational modifications on proteins or 
alternative splicing events.  
2.1 Significance 
There are a number ways in which proteomics may be utilized in personalized medicine 
and more broadly in drug discovery, research and development. In its simplest application, 
proteomics has contributed to the discovery of disease biomarkers, clinical entities that 
define and /or predict normal and pathogenic states (Krejsa et al., 2006). Furthermore, the 
clinical response to treatment can be monitored through proteome profiling of relevant 
biomarkers. The clinical use of a biomarker is contingent on whether it is a validated 
biomarker, which ultimately depends on its clinical reliability and utility. Combinations of 
validated markers biomarkers can indicate surrogate endpoints that can predict clinical 
outcomes. On a more global protein expression level, comparative proteomics can generate 
patterns of protein expression or expression profiles, which may be utilized to define a 
specific physiological state, or diseased state.  
One area where proteomics can yield information not possible by other means is the 
identification and localization of proteins in various cellular compartments and extracellular 
space. The paradigm that proteins have fixed locations within cells has recently proven to be 
simplistic, and that proteins have diverse functions depending on their cellular location. The 
identification of a protein outside of its known functional zone in cellular preparations was 
once thought to be due to rupture of cells/cell organelles and leakage of the protein into 
other fractions. However it is now known that proteins translocate between intracellular and 
extracellular compartments (Butler et al., 2009). This has enormous implications in drug 
targeting as the presence of a target in multiple locations may complicate therapy. For 
example, chaperone proteins, including HSP 10, 70 and 90 have now been shown to exist in 
extracellular locations, where it was once thought that the chaperone proteins were 
exclusively located intracellularly, to aid protein folding and carry out chaperone function. 
Inhibitors of HSP90α are in clinical trials for treatment of cancer (Banerji, 2009), however 
inhibition of the extracellular wound-healing function of HSP90α21 could be an undesired 
adverse effect.  
2.2 Personalized medicine for cancer 
Due to the great diversity of cancer types, and individual variation within specific tumours, 
cancer perhaps shows the greatest potential for development of personalized therapy. 
Cancer accounts for about 13% of all deaths annually world wide, and is a major cause of 
morbidity and mortality (Krause-Heuer et al., 2009). Notwithstanding the emergence of new 
chemotherapeutic drugs and novel therapies for cancer, significant challenges remain for 
understanding tumourigenesis and tumour cell biology, and in developing new, effective 
strategies for cancer treatment. (Mozafari et al., 2009). Some of these challenges include; 
 Identification  of new tumour targets  
 Drug potency, due to inadequate concentration at the cell surface. 
 Non-selective nature of cytotoxic agents and a low therapeutic index. 
 Development of multi-drug resistance (MDR)  
The development of therapeutic monoclonal antibodies (mAbs) has shown promise in 
treatment of cancer amongst other indications. At present there are around 30 approved 
therapeutic mAbs predominantly for treating cancer and diseases associated with 
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inflammation (Walsh, 2010). Anti-cancer antibodies are designed to target tumour cell 
surface antigens, with subsequent eliciting of an immune response on tumour binding. Most 
commonly this is termed antibody dependent cellular cytotoxicity (ADCC), and activated 
natural killer cells are recruited to attack the tumour. Currently approved anti-cancer 
therapeutic mAbs targeting the tumour cell surface are specific for antigens including EGFR, 
HER2/neu, CD20, CD52 and CD33. Other targets which are receiving much attention are the 
mucins, principally MUC1 (there is no existing approved antibody for MUC1), IGFR and 
CEA and cancer stem cell antigen CD44. The future development of monoclonal antibody 
(and other) cancer therapies will be contingent on the identification, development and 
validation of new tumour targets. However identification of new tumour biomarkers that 
reliably and accurately diagnose early stage cancer has not been met with great success. As 
an example, a group of researchers, as part of the Early Detection Research Network 
(EDRN), tested a group of recently discovered putative biomarkers for ovarian cancer, 
however none were superior to CA-125, which has been used extensively for 30 years. 
Notwithstanding the significant challenges in the discovery and development of clinically 
useful biomarkers, proteomics will be central for the discovery of new, novel biomarkers for 
early detection and diagnosis; some of these biomarkers may be suitable for development as 
novel drug targets (Pastwal et al., 2007).  
Recently the International Cancer Genomes Consortium (ICGC) was formed, with a charter 
to co-ordinate and integrate large-scale cancer genome sequencing projects, focusing on 50 
different types of cancers (The International Cancer Genome Consortium, 2010). The 
expanded studies will consist of investigating around 25,000 specific cancers (biopsy 
material from individuals). The primary objectives of the consortium were made public in 
April 2008 and were released in April 2008 (http://www.icgc.org/files/ICGC_ April_29_2008. 
pdf). However these studies will be at the genomic, epigenomic and transcriptomic levels. 
At the proteomic level, the Human Proteome Organization (HUPO, http://www.hupo.org/) 
instigated the Human Proteome Project (HPP), a co-ordinated global initiative to map the 
protein-based molecular architecture of the human body. This initiative, will aid in the 
discovery and cataloging of new tumour associated antigens and potential targets. 
2.3 Evolution of methods of analysis using proteomics 
The term proteomics, encompassing the analysis of and tools used to examine proteins 
expressed by a genome was coined only about 15 years ago (Wilkins et al., 1996). The 
progression and development of proteomics since this time however, has naturally afforded 
a refinement in techniques and methods for simultaneously detecting, identifying and 
quantifying proteins in biological samples. Fundamental to any identification or further 
characterization is the ability to first separate proteins from complex samples. This is 
particularly important for samples such as blood where it is estimated that the dynamic 
range of proteins is greater than 10exp9. With such a vast dynamic range, just 22 proteins 
account for 99% of protein content in blood (reviewed in Simpson et al., 2008). With respect 
to the search for protein biomarkers, the situation is also complicated by the notion that 
most biomarkers will be low abundance proteins. As protein function and levels of 
abundance are often altered in disease states, identification of such changes by comparison 
of healthy and disease samples will allow a greater understanding of the disease, provide 
new therapeutic targets, as well as identify markers of disease status. Establishment of what 
could be defined as the “healthy phenotype”, will depend on detailed characterization of the 
proteomes of healthy and diseased states of cells/tissue. One school of thought suggests that 
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by creating complex “proteomic fingerprints” of healthy and diseased states (and transitions 
thereof), one may recognize perturbations from the healthy state phenotype before 
manifestation of the disease state. Therapeutic intervention during the transition-to-disease 
state may instigate a reversion to the healthy phenotype. Thus a systems biology approach 
to studying the proteomes of cells in normal and diseased states, and also the network of 
protein-protein interactions, should enhance the opportunity for attaining this goal.  
Proteomics and the tools to identify and quantify proteins have evolved substantially since 
its conception. The availability of genomic information, particularly the complete human 
genome sequence has in many ways pushed the bottleneck from the genomic to proteomic 
arena. Developments include tools for protein separation, protein identification, 
quantification and automated processes. The following sections provide a summary of some 
of the major approaches to protein separation, identification and quantification using both 
gel and gel-free proteomic methods. Separation of proteins can be based on one or more 
physical or biochemical parameter including size, pI, sub-cellular location, or other 
depletion / enrichment strategies, with separation involving two or more ‘orthagonal’ 
approaches providing greater separation than a single dimension alone. 
2.3.1 Two-dimensional gel electrophoresis 
One of the earliest approaches to protein separation was based on the use of two-
dimensional gel electrophoresis (2DGE), in which proteins are first separated by charge in a 
pH gradient (isoelectric focusing), followed by separation based on size in SDS-PAGE gels 
(O’Farrell, 1975). The gel is subsequently stained to visualize proteins, with each protein 
spot-volume representative of abundance of the protein(s) within it. This approach, 
particularly when combined with other upstream fractionation steps (e.g. sub-cellular) can 
provide separation and resolution of a large number of proteins (Cordwell et al., 2000) and 
has been used in various projects aiming to identify differentially expressed proteins – 
potentially biomarkers, by comparing control vs. diseased samples via gel-analysis software 
and statistical tests. Using 2DGE, identification of candidate biomarkers has been achieved 
for a range of diseases including atherothrombotic ischemic stroke (Brea et al., 2008), 
pancreatic cancer (Park et al., 2011) and breast cancer (Lee, et al., 2011) with many studies 
identifying new potential markers.  
2.3.2 Differential In-Gel Electrophoresis (DIGE) 
Improvements to 2DGE include the addition of small fluorescent tags (CyDyes) on protein 
samples prior to separation, thus allowing multiple samples to be combined in the same 
physical gel (Tonge et al., 2001). This approach, known as Differential In-Gel Electrophoresis 
or DIGE, circumvents some of the problems of quantifying proteins across different samples 
in different gels as the distinct fluorescent tags on different samples allow the researcher to 
detect proteins from control vs. disease samples simultaneously. The inclusion of a pooled 
internal standard representing a mix of all samples can help circumvent some of the 
technical difficulties (e.g. gel warping and spot matching) that arise from single-sample gels.  
An advantage of DIGE is that due to the sensitive fluorescent nature of the CyDye labels low 
amounts of sample (as little as 10 g) are required for analysis. However, a caveat is that 
although protein separation and quantification can be achieved, the identity of the proteins 
still remains unknown unless the protein spots are excised and further analysed, which can 
be difficult due to the low amounts of protein used in the analysis. Limitations also exist in 
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the dynamic range of protein detection, estimated at 10exp4 (reviewed in Rabilloud, 2002) 
Typically a separate, unlabelled gel with larger amounts of protein loaded are required to be 
run and subsequently cross matched with the original DIGE experiment, as described by 
Matigian et al., 2010. Despite these difficulties, 2DGE has a proven track record in the 
separation and identification of proteins, with numerous differentially expressed proteins 
and potential biomarkers uncovered. 2DGE has been applied to a wide range of sample 
types including tissues (e.g. breast, skin, brain) and fluids such as cerebrospinal fluid, 
serum, urine, and tears targeting diseases such as various cancers, Alzheimers disease and 
dementia, cardiovascular diseases, infections such as HIV, conjunctivitis and toxoplasmosis. 
Overall, 2DGE with or without fluorescent labeling of samples does provide good 
separation of proteins, but is time consuming and a laborious process both in the gel 
procedures, and analysis of 2D protein spot profiles.  
2.4 Mass spectrometry-based approaches 
Mass spectrometry (MS) has formed the basis for standard protein identification for many 
years, typically in a ‘bottom-up’ approach (in which proteins are digested, usually with 
trypsin) and the resulting peptides analyzed to determine protein identity, but also in some 
cases by ‘top-down’ approaches where intact proteins form the basis of analysis. MS-based 
approaches hold some advantages over traditional 2DGE methods in that samples can 
potentially be analyzed and identified simultaneously through methods such as two 
dimensional LC-MS/MS using a combination of strong cation exchange followed by reverse 
phase separation of peptides. In comparison to gel-based approaches, MS analyses appear to 
be more effective at identifying low abundance proteins, as well as those with extreme 
physical properties such as molecular weights (low or high) or pI values, which are often 
difficult to resolve on gels. MS-based analyses also offer better prospects for automation of 
separation, analysis and identification of proteins.  
With the ability to rapidly identify large numbers of proteins via MS, the emphasis has since 
shifted to also quantifying those proteins detected by MS. Broadly speaking, the approaches 
to quantifying proteins via mass spectrometry can be based on labeled or label-free 
methods. Each approach has its own advantages and disadvantages. Label-based methods 
include Isotope-Coded Affinity Tag or ICAT, and Isotope Tag for Relative and Absolute 
Quantitation or ITRAQ, in which multiple samples can be labeled, mixed and then analyzed 
simultaneously via MS to avoid technical issues relating to reproducibility that may be 
encountered with label-free approaches.  
2.4.1 ITRAQ, ICAT and SILAC 
ICAT and ITRAQ differ in their labeling chemistries and site of attachment. For ICAT, 
cysteine (cys) residues are targeted and selected for via avidin affinity chromatography. The 
enrichment of only those cys-containing peptides provides one avenue to quantify samples 
without the complexity of analyzing all peptides in a sample. However, ICAT becomes 
problematic for analysis of proteins which lack any cys residues. Furthermore, as reviewed 
in Patton et al., 2002, approximately 70% of proteins contain four or less cys residues thus 
limiting the usefulness of this approach.  
ITRAQ utilizes lysine residues for labeling (Ross et al., 2004), thus avoiding the problem of 
limited cys residues encountered with ICAT. ITRAQ is a multiplexed approach, where tags 
are based on isobaric reagents. This means that up to eight different samples can be labeled 
www.intechopen.com
Evolution of Proteomic Methods for Analysis of  
Complex Biological Samples – Implications for Personalized Medicine 
 
35 
with unique tags. The physical properties of the tags differ only in the isotopes used in their 
synthesis, meaning during LC separations, and in MS mode are identical. Only upon 
fragmentation in MS/MS mode are the isobaric tags distinguishable. The result is that 
proteins can be identified via MS/MS and due to unique reporter ions from the ITRAQ tag, 
the protein can also be quantified. The initial ITRAQ labels were designed to label up to four 
different samples, although tags to label and detect up to eight different samples are now 
available. Limitations for ITRAQ lie with the difficulty of identify proteins and quantify 
them when uniquely expressed in only one sample type eg a protein expressed only in the 
diseased state. Some technical difficulties, in particular with 8plex tags, resulting in a 
reduction in identification efficiency have also been reported (Thingholm et al., 2010). 
Other label-based strategies such as Stable Isotope Labeling with Amino acids in Cell 
culture (SILAC) also exist. This method is based on labeling proteins in culture with heavy 
and light forms of amino acids. The approach is a useful way of comparing two samples, but 
is limited only to cells grown in culture or in some cases, animal models (Zanivan et al., 
2012) and would not be applicable to human or clinical studies due to the use of 
radioactivity.  
2.4.2 Selected reaction monitoring / multiple reaction monitoring 
Selected reaction monitoring (SRM), also known as Multiple Reaction Monitoring (MRM) 
provides a targeted approach to quantifying proteins in a sample. It advances the ‘global’ 
approach to quantification by simply targeting those proteins specifically of interest to the 
researcher. Typically MS instruments such as triple quadrupoles are used, where a 
precursor mass representing a peptide (typically tryptic) from the protein of interest is 
selected, fragmented and specific product ions unique to that peptide, monitored. Generally 
for each protein of interest a number of precursor ions, and subsequent product ions are 
monitored to ensure specificity. This information is then used to identify and quantify the 
proteins present. The main limitation of SRM/MRM analyses is that it is essential to know 
the proteins of interest beforehand, so that appropriate precursor / product ion can be 
monitored.  
SRM / MRM is a targeted approach, where identify of the protein(s) of interest must be 
known beforehand. The usefulness of SRM/MRM analyses is thus as a downstream 
technology after discovery-phase experiments have concluded, and candidate proteins of 
interest requiring quantification already identified. The advantage of SRM / MRM assays is 
the ability to simultaneously monitor numerous potential biomarkers in a single analysis 
and quantify protein levels and is thus currently a popular area of investigation. To help 
with SRM / MRM analyses, a consortium called SRMAtlas has been established 
(www.mrmatlas.org) to quantify proteins in complex samples by MS. As well as human 
entries, mouse and yeast information is also contained, and provides both web-interface and 
command line tools to search for assays. This readily available information means 
researchers can potentially circumvent some method development steps as optimal 
coordinates for SRM / MRM transitions of numerous proteins are available.  
2.4.3 Stable isotope standards and capture by anti-peptide antibodies 
Stable isotope standards and capture by antipeptide antibodies (SISCAPA) is a method 
which allows the quantification of peptides from complex digests. Originally described by 
Anderson et al., 2004 the method utilizes stable-isotope-labeled internal standards for 
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comparison with (unlabelled) peptides that are enriched via anti-peptide antibodies, with 
subsequent quantification performed by electrospray mass spectrometry. The approach 
offers increased sensitivity over non-enriched methods, particularly when coupled with 
SRM / MRM assays. SISCAPA also offers potential in the verification of diagnostic protein 
panels from large samples as well as increased efficiency in assay time for the bind/elute 
process over conventional reverse phase separations. There are also distinct advantages over 
traditional techniques such as ELISA in development time for biomarker assays (Whiteaker 
et al, 2009). The main disadvantage of SISCAPA is the need for preselected targets, as well 
as the cost in producing the internal peptide standards and generation of the peptide 
binding antibodies. However, given the sensitivity of the assay (only low fmol – pmol 
amounts are required), and the fact the antibody itself can be recycled and used again means 
on-going costs can be reduced. Since the original design of SISCAPA, refinements in the 
assay have been developed to reduce loss of low abundance peptides, automated processing 
steps, and improvement in antibody sources i.e. from polyclonal to monoclonal (Anderson 
et al., 2009; Schoenherr 2009). As this method is only a relatively recent development, no 
biomarkers have as yet been published as validated with this approach, although proof-of-
principle experiments have been performed with established biomarkers such as tropinin I 
(cTnI) (Kuhn, et al., 2009) and thus SISCAPA remains a promising tool.  
2.4.4 Alternative strategies 
In addition to the above technologies, other strategies have been developed to complement 
gel and MS approaches to detect biomarkers through improved sample preparation 
methods. For example, hexapeptide libraries, based on combinatorial peptide libraries offer 
a way to deplete samples of highly abundant proteins (Guerrier et al., 2008). In this 
innovative technique, a large collection of specific hexapeptides (hexapeptide library) is 
attached to beads. The complex protein sample of interest is mixed with the hexapeptide-
bead library. The peptide library is of high diversity and so it would be expected that a 
specific peptide(s) in the library would have affinity for each individual protein in the 
complex sample. After separation of the beads from the mixture, the adsorbed proteins are 
eluted from the beads. As each hexapeptide is equally represented within the library, the 
end result is that the abundant proteins are depleted, while proteins of low abundance are 
concentrated. This approach is particularly useful for biological fluids (serum, saliva, urine 
etc) which have particularly large dynamic range of protein abundance. For example, 
hexapeptide enrichment of urine has uncovered an additional 251 proteins that were not 
previously known to be present in this fluid (Castagna et al., 2005). Although 
depletion/enrichment strategies may not, in their own right, uncover biomarkers, their 
usefulness lies in the ability to mine deeper into the proteome of these highly complex 
samples so that low abundance proteins can be identified.  
Depletion / enrichment strategies can be problematic if the abundant protein is a carrier 
for low abundance molecules and the use of depletion strategies must be done with 
caution. For example it has been shown that the depletion of albumin from human plasma 
can also remove low abundance proteins such as cytokines (Granger et al., 2005). More 
recent studies (Bellei et al., 2010) have also concluded that removal of high-abundance 
proteins can result in a loss of non-targeted, less abundant proteins. Obviously 
unintentional and unknowing loss of low abundance proteins is a cause for concern in the 
search for biomarkers of disease.  
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Other approaches for analysis of samples include Surface Enhanced Laser Desorption 
Ionisation (SELDI) and Matrix Assisted Laser Desorption Ionisation (MALDI), which have 
both been utilised particularly in examination of body fluids such as serum for biomarker 
discovery. This is effectively a ”protein pattern recognition“ approach (reviewed in Zhan & 
Desiderio, 2010) which compares profiles from control versus disease samples to identify 
those proteins differentially expressed. This approach has been used in particular for 
analysis of cancer patients.  
2.4.5 Post-translational modifications 
The majority of the above technologies focus on protein expression and differential 
expression in control vs. disease states. However, greater emphasis in the future on protein 
post-translational modifications (PTMs) such as glycosylation and phosphorylation will be 
needed. Already, perturbations in modifications of proteins by the glycan O-linked B-N-
acetylglucosamine (O-GlcNAc) has been implicated in a range of diseases, including 
Alzheimers and diabetes (reviewed in Dias & Hart 2007). Similarly, differential 
phosphorylation has been identified in diseased states such as cancer compared to control 
patients (Semaan et al., 2011). 
2.4.6 The Human Proteome Project 
Fundamental to rational design for disease treatment and prevention is the understanding 
of genes present, and the expression and function of gene products, including proteins 
involved in the disease process. The Human Genome Project (HGP) was established to map 
all genes encoded in the human genome. Surprisingly, the total number of protein coding 
genes, only approximately 20,300, was substantially lower than expected, with increased 
complexity presumably due to splice variants, and post-translational modifications. 
Following on from this ground-breaking work, is the recent establishment of the Human 
Proteome Project which aims to map the human proteome (Legrain et al., 2011). At present, 
of the protein-coding genes in humans identified in the human genome, approximately one 
third have not been detected at the protein level, while for many others, basic information 
such as abundance, sub-cellular localization, or function are unknown. Mapping of the 
proteome will be valuable in understanding human biology, and downstream applications 
in developing diagnostics, prognostics and new therapies to treat diseases. The HPP will 
have a ‘gene-centric’ approach to map information about proteins back to gene loci. HPP 
will aim to address three parts (HUPO Views, 2010): 
 Identification and characterization of proteins from every gene. 
 Distribution of proteins in all normal tissues and organs. 
 Mapping of pathways and protein networks and interactions.  
With respect to sample type, bodily fluids relatively easily attainable, such as urine, 
saliva, tears as well as those requiring more slightly more invasive methods for collection 
such as serum, plasma and CFS have all been analyzed for a variety of diseases. Fluids as 
opposed to solid tissues would generally form a better basis for determining personalized 
signatures and biomarker detection due to their ease of attainment. There has been some 
question over whether blood is the best choice for searching for biomarkers. The rationale 
has been that specific proteins are secreted by the body from different organs, and that 
these can represent a biological ”fingerprint” of physiological state (reviewed in Simpson 
et al., 2008).  
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Using model systems such as mice, researchers have shown changes in the plasma proteome 
prior to any clinical evidence of breast cancer (Pitteri et al., 2011). A separate study in 
humans (Li, 2011) also suggests that it may be possible to observe proteome plasma changes 
prior to diagnosis. Plasma proteomics has also been used in the search for pre-diagnostic 
markers in other diseases such as coronary heart disease (Prentice et al., 2010). The ability to 
identify proteome changes prior to manifestation of disease phenotypically, will potentially 
improve patient outcome, particularly for those diseases such as cancer where early 
diagnosis strongly correlates with survival rates.  
3. Conclusion 
The ability to define proteomic “signatures”’ for individuals will vastly enhance the ability 
of the medical community to diagnose and treat diseases, as well as potentially identify 
disease before symptoms appear. Early treatment will in turn prolong life, as well as 
potentially address healthcare costs through the application of more refined and defined 
therapies suitable for individual patients. The heterogeneity of some diseases such as breast 
cancer, in which specific proteins, e.g. progesterone receptor, estrogene receptor and HER-2 
may or may not be expressed, make it difficult to broadly treat patients, as a ‘one size-fits 
all’ approach does not always apply, and emphasizes the need for individualized and 
personalized medicine. By examining the proteome, it is possible to gain a better 
understanding of the heterogeneity present in an individual and potentially can help 
determine best choice of therapies, as well as indicate disease status and progression. Given 
the complication of genetic factors and environmental influences on an individual, 
personalized medicine strategies will require complementation of proteomic data with other 
areas and strategies for analysis and compile this information to determine diagnostic 
approaches and tailor therapeutic strategies for the individual.  
As yet, despite the excitement of biomarker discovery, and the vast number of publications 
claiming detection of biomarkers for a specific disease, the majority of candidate biomarkers 
are yet to be validated or used in clinical settings. However, once candidate biomarkers are 
confirmed, the emphasis will be on high-throughput approaches to expand analyses to 
greater numbers of samples. Clearly the proteomic tools available to detect and characterize 
samples, particularly in a high-throughput quantitative fashion are now a reality. Thus, 
personalized medicine is not far off the horizon. We anticipate a new era of therapeutic 
approaches and more refined medicinal treatments for diseases which will be more targeted 
and precise, not just for the disease, but for the individual, based on establishment of 
“proteomic fingerprints”. In addition to greater confidence in diagnoses, proteome 
signatures would allow a more individualized and targeted approach to therapy. 
Potentially, such signatures may also provide better insight into future recurrences of the 
disease.  
Besides the quest for discovery, research and development of new and unique biomarkers, 
other facets of biomarker research incorporate aims such as improving reliability, increasing 
the speed of detection and reducing the amount of sample needed for analysis. However, 
the search for biomarkers is particularly important for those diseases such as breast cancer, 
for which there are no current clinical biomarkers available, and for which mortality is 
tightly related to disease stage in the initial surgery (Bohm et al., 2011). Using proteomics 
however, a biomarker signature for non-metastatic breast cancer has been uncovered. This 
study (Bohm et al., 2011) found using serum samples and SELDI-TOF and MALDI-
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TOF/TOF analyses, a combination of 14 biomarkers that can identify breast cancer patients 
from controls, with a specificity of 67%. It is unlikely at this stage that this panel or signature 
will entirely replace imaging diagnostics, but does have the potential to aid current 
diagnostic approaches, particularly when cancer survival rates are greatly improved with 
early detection, while tumors <5 mm are normally not detected.  
One of the fundamental problems of assigning ‘biomarker’ status for a protein found to be 
differentially expressed in a disease is the overlap of these differentially expressed proteins 
across different diseases. A number of proteins have been implicated across a number of 
different diseases, making the notion of a single biomarker to indicate a specific disease 
more difficult. For example, serum amyloid A has been proposed as a prognostic marker for 
melanoma (Findeisen et al., 2009), breast cancer (Schaub et al., 2009), atherothrombotic 
ischemic stroke (Brea et a., 2009). Potentially, for greater confidence in disease diagnosis or 
prognosis, it may be required that a suite of biomarkers, be needed to provide greater 
specificity and confidence.  
The significance of the future development of personalized medicine is far reaching, and 
will allow/facilitate the following:  
 Predicting a patient’s response to drugs. 
 Development of customized’ prescriptions. 
 Minimizing, or in some cases eliminating adverse events. 
 Improving rational drug development. 
 Improving drug R&D and the approval of new drugs - better designed clinical trials 
based on genomic/proteomic information. 
 Screening and monitoring certain diseases e.g. advanced diagnosis before disease 
symptoms.  
 Reducing the overall cost of healthcare. 
If the concept of routine personalized medicine is to become a reality in the future, the 
development of new proteomic techniques and methodologies will be vital, and will build 
on current methodologies now available.  
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